Search Results
Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC
Dr. Ross Camidge Discusses Crizotinib in ROS1 Rearranged NSCLC
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC
Dr. Camidge on the PROFILE 1007 Trial: Crizotinib vs Pemetrexed or Docetaxel in NSCLC
GRACEcast-086_Lung-Cancer_Q&A with Drs. Solomon and Camidge on ALK Inhibition for Advanced NSCLC
Upfront treatment of ROS1-rearranged NSCLC
Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion – Video abstract ID 136297
Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC
D. Ross Camidge Discusses the Development of a New Lung Cancer Drug
Dr. Riess on ROS1 Fusions in Lung Cancer
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
